Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer	Eli Lilly	Ongoing	abemaciclib	3	I3Y-MC-JPCF	King Fahad Medical City (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam)
A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	Novartis	Ongoing	ABL001	3	CABL001A2301	King Faisal Specialist Hospital and Research Center (Riyadh)
Follow-up of Phase I/II study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR αβ+T cells in pediatric patients affected by hematological disorders	Bellicum Pharmaceuticals	Ongoing	Rimiducid	2	CT17-008-R	King Abdulaziz Medical City NG (Riyadh)
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Angiotec tablets (20 mg enalapril) Produced by JPM / Jordan versus Renitec® tablets (20 mg enalapril) Produced by Merck Sharp & Dohme / UK, in healthy subjects under fasting condition.	SFDA	Ongoing	Angiotec	BE	Jun-17	Saudi Ajal
An observational disease and clinical outcomes registry of patients with acid lipase (LAL) deficiency	Alexion Pharma International Sàrl.	Ongoing	Kanuma	4	ALX-LALD-5	King Faisal Specialist Hospital and Research Center (Riyadh)
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Arena film-coated tablets (150 mg irbesartan) Produced by Jamjoom/ KSA versus Aprovel® film-coated tablets (150 mg irbesartan) Produced by Sanofi-aventis / Germany, in healthy subjects under fasting condition.	SFDA	Ongoing	Arena	BE	Aug-17	Saudi Ajal
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Capocard tablets (25 mg captopril) Produced by Dar AlDawa / Jordan versus Capoten® tablets (25 mg captopril) Produced by SPIMACO / KSA, in healthy subjects under fasting condition.	SFDA	Ongoing	Capocard	BE	Jul-17	Saudi Ajal
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Biscor film-coated tablets (10 mg bisoprolol fumarate) Produced by Pharma International / Jordan versus Concor® film-coated tablets (10 mg bisoprolol fumarate) Produced by Merck / Germany, in healthy subjects under fasting condition.	SFDA	Ongoing	Biscor	BE	Sep-17	Saudi Ajal
Randomized, three-way, three-period, single oral dose, open-label, crossover, bioequivalence study to compare Lipomax tablets (20 mg atorvastatin) Produced by SAJA / KSA, versus Lipitor® tablets (20 mg atorvastatin) Produced by Pfizer / Ireland, in healthy subjects under fasting conditions.	SFDA	Ongoing	Lipomax	BE	Nov-17	Saudi Ajal
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Pedovex film-coated tablets (75 mg clopidogrel) Produced by Tabuk / KSA versus Plavix® film-coated tablets (75 mg clopidogrel) Produced by Sanofi-aventis / KSA, in healthy subjects under fasting condition.	SFDA	Ongoing	Pedovex	BE	Oct-17	Saudi Ajal